Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT07571161

1 development in the corpus

NCT07571161

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 6, 2026 · PHASE 3 TRIAL

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

ClinicalTrials.gov

This is an active Phase 3 trial registration with no results reported; donanemab's efficacy and safety in Chinese preclinical AD remain unevaluated pending completion.

PreliminaryEli Lilly and Company Donanemab Alzheimer Disease

Reported

Planned enrollment140

PhasePhase 3

Primary outcome measureTime to Clinical Progression as Measured by…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support